ABOUT ONCOSENX
OncoSenX is a late stage pre-clinical cancer company headquartered in Seattle, Washington. OncoSenX targets solid tumors based on transcriptional activity using a unique Proteo-Lipid Vehicle (PLV) and plasmid DNA.
OUR MISSION
The next generation in cancer therapies will be more targeted with less side effects. At OncoSenX we believe the battle against cancer should be fought with genetic information. Our treatment delivers a simple program that induces apoptosis in cancerous cells. Our approach is a less invasive, more precise intervention for this complex and devastating disease. The next generation of cancer therapies has begun...
SCIENCE
OUR SYSTEM
Our system is comprised of two main components: An untargeted non-toxic Proteo-Lipid Vehicle (PLV) and a highly targeted DNA payload.
CELL TARGETING
DNA plasmids encode an inducible death protein under a promoter that is active in the target cell population. We are initially targeting cells that are transcriptionally active for p53.
Cells are killed via apoptosis with caspase 9.
We can use our DNA payload to effectively implement logic gates (IF/OR/AND). This allows us to precisely target cell populations based on their genetic activity without harming adjacent cells.
DELIVERY
Our patented Proteo-Lipid Vehicle (PLV) is the transfection agent that efficiently delivers our non-integrating DNA plasmid to cancer cells
These PLVs have been shown to be non-immunogenic, even with adjuvant, and are non-toxic at doses up to 10x expected human therapeutic dose in rodents and non-human primates.
SAFETY
Anti-PLV antibody & neutralization assays:
Virtually no antibody response to PLVs in immune-competent mice, even with adjuvants
Neutralization requires very high antibody concentration
“Vaccination” against PLVs does not reduce efficacy
Repeat dosing is effective and well tolerated
CARPA Assays
PLVs are generally less reactive than other lipid drug formulations
Our Partners
TEAM
MATTHEW SCHOLZ
Chief Executive Officer
Matt is a co-founder of OncoSenX and serves as CEO and Chairman. A serial entrepreneur with a background in computer security and immunology, Matt is also the founder and CEO of Oisín Biotechnoligies and former CEO of Immusoft, a biotech firm developing a breakthrough technology that will turn a patient's B cells into miniature drug factories. He’s a graduate of the University of Washington and a frequent speaker at the UW School of Business.
JOHN D. LEWIS, Ph.D.
Chief Science Officer
Dr. John Lewis the co-founder of OncoSenX and heads its cancer-fighting platform technology development and clinical research. Dr. Lewis also holds the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta. He is a Professor in the Department of Oncology and chairs the Alberta Prostate Cancer Research Initiative. Dr. Lewis has also founded three Canadian biotechnology companies.
GARY C. HUDSON
Board Member
Gary Hudson is co-founder and Board Member of OncoSenX. Mr. Hudson is also active in several non-profits focusing on age-related disease. Mr. Hudson has won several awards during his career including Laurel Award from Aviation Week and Space Technology, the Founder’s Award from the Space Frontier Foundation and was inducted into the International Space Hall of Fame in 2014 for his contributions to the field.
ERIC GARCIA
Chief Operating Officer
Eric Garcia is the Chief Operating Officer, Treasurer and co-founder of OncoSenX. He has responsibility for the company’s finances and business operations. Mr. Garcia also helped start Oisin Biotechnologies, serving as its COO. Prior to Oisin Biotechnologies Mr. Garcia was the Chief Financial Officer for the immunotherapy biotech, Immusoft Corporation. Outside biotechnology, Mr. Garcia has worked in financial management and public policy.
Jailal Ablack, PhD
Head Of Preclinical Research
Jai received his Ph.D. in Microbiology and Immunology from the University of Western Ontario in 2011 with a research focus in viral oncology. Jai relocated to San Diego to Post- Doc in the Department of Medicine at UCSD expanding his interests to include mechanisms of cancer proliferation control and cancer therapeutics. In 2019, Jai joined OncoSenX to helm their pre-clinical research program.
Hank Garcia, PhD
Senior Scientist
Hank received his Ph.D. in Cancer Genetics and Cellular and Molecular Biology from the Roswell Park Cancer Institute in 2014 with a research focus on drug development and tumor initiation. Hank then took a position as a Post-Doc in the Department of Anatomy at the University of California San Francisco, expanding his research expertise to include neurobiology and aging therapies. Hank now supports OncoSenX’s R&D efforts.
STEPHEN HILBERT
Chief Business Officer
Mr. Hilbert is the Chief Business Officer for OnocoSenX. He has served as business advisor since its inception and has served on several biotechnology company advisory boards specializing in business strategy and capital formation. Prior to OncoSenX in the Biotech space, Mr. Hilbert has served as corporate advisor to Immusoft and Kineta where he most recently served as VP of Corporate Development. His career spans over 10 years in biotech advisory and 18 years in the banking where he served as Vice President creating investment strategies and structures for accredited investors around the globe at JP Morgan and Charles Schwab.
NEWS
Keep up with the latest about OncoSenx
Articles
Videos
OncoSenX 3 Minute Intro
December, 2020
OncoSenX targeting solid tumors with its unique technology
Proactive | January 14, 2020
ARM Cell and Gene Therapy Meeting on the Mesa (Matt Scholz)
October 3, 2019
CORPORATE HEADQUARTERS
701 Fifth Ave, Suite 4200
Seattle, Washington 98104
INQUIRIES